Chris Hill
Analyst · Piper Sandler. Please go ahead
Thanks, Larry. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls specifically excluded the impact of any FX gains or losses and assumed an effective tax rate of 20%. So accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. Now let's review the income statement. Revenue from continuing operations was $125.1 million in the fourth quarter, up over 6% from $118 million in the prior quarter and up 10% year-over-year. The growth in revenue was driven by increased activity associated with international projects which grew over 11% sequentially and over 14% year-over-year. Although COVID-19 disruptions continue to persist, activities on international projects improved and continue to gain momentum in the fourth quarter. For the full year 2021, revenue was $470.3 million and is on a growth trajectory as we exited the year. However, it is down about 3% from 2020. Of this revenue, service revenue, which is more international, was $89.3 million for the quarter, up over 5% sequentially from $84.8 million last quarter. As stated earlier, we had a nice improvement in activity levels on international projects, which increased over 6% and slight improvement in the U.S. markets, which was led by a nice pickup in our Well Diagnostic Services. Product sales, which is equally tied to North America in the international activity, were $35.9 million for the quarter, an increase of over 8% from $33.2 million last quarter and up 46% year-over-year. Product sales associated with perforating systems were up sequentially in both the U.S. and international markets. The fourth quarter included some large international orders, which can vary from quarter-to-quarter. The growth in perforating product sales in the fourth quarter was partially offset by a decrease in sales of laboratory instrumentation, which have longer lead times and can also vary from quarter-to-quarter. Moving on to cost of services, ex items for the quarter are 78% of service revenue and improved slightly when compared to 79% last quarter. As discussed in previous quarters, cost of services were expected to increase as we restore some of the temporary cost reduction measures previously put in place during the pandemic. As we progress further into the recovery with operational activity and our laboratory utilization improving and as employee costs are significantly restored, our incremental margins on services will improve and trend towards historical norms. Cost of sales ex items in the fourth quarter was 75% of revenue compared to 78% last quarter and continues to improve as activity increases. As product sales continue to grow, manufacturing efficiencies and absorption of fixed costs will also continue to improve. However, inflationary pressures on raw materials, labor, packaging and transportation have increased, which are expected to increase cost of sales for products. G&A ex items for the quarter was $10.9 million, up from $8.6 million last quarter. The sequential increase in G&A cost is primarily due to restoration of employee compensation costs and a higher level of costs associated with maintaining and improving our cybersecurity. G&A ex-item was $36.9 million for the full year, down from $38.6 million for the full year 2020. For 2022, we expect G&A to be approximately $40 million. Depreciation and amortization for the quarter was $4.4 million and comparable to last quarter. For the full year, depreciation and amortization expense was $18.5 million, down from $20.9 million in 2020. Capital expenditures were $3.5 million for 2021, up from $11.9 million last year. However, the 2021 capital expenditures include approximately $2 million associated with repair damage facilities, which was primarily caused by the severe North American freeze in February of 2021. Damage to the facilities was substantially covered by insurance less our deductibles. EBIT ex-items for the quarter was $14.2 million, up 9% from $13 million last quarter, representing an EBIT margin of over 11%. The company continued to restore personnel compensation during the quarter and was able to maintain EBIT margins at 11%. Our operating income for the quarter on a GAAP basis was also $14.2 million. Full year 2021 EBIT ex-items was $52.3 million and generated EBIT margins of over 11% for the full year. Interest expense was $2.6 million comparable to last quarter, but down from $2.9 million in the same quarter last year. Interest expense ex-items for the full year was $11 million, down approximately 12% from $12.5 million in 2020. The decrease in interest expense reflects the reduction of long-term debt throughout the year. On a GAAP basis, we’ve recorded interest expense of $9.2 million in 2021, down from $14.4 million in 2020. Income tax expense ex-items and using an effective tax rate of 20% for the quarter was $2.3 million. On a GAAP basis, the company recorded income tax expense of $8.8 million. Higher tax expense for the quarter was largely impacted by foreign currency gains, primarily in Turkey where unrealized foreign currency gains associated with U.S. dollar-denominated receivables are subject to tax locally. The company has taken additional steps to further mitigate this type of foreign currency risk and does not anticipate additional tax expense associated with foreign exchange rates to reoccur in future periods. Now looking forward to 2022, we project the company's effective tax rate to be approximately 20%. The effective tax rate will continue to be somewhat sensitive to geographic mix of earnings across the globe and the impact of items discrete to each quarter. Income from continuing operations ex-items for the quarter was $9.3 million, up 12% sequentially from $8.3 million last quarter. For the full year 2021, ex-items, it was $33 million, down from $35.3 million in 2020. GAAP income from continuing operations for the quarter was $2.8 million, and for the full year 2021 was $20.2 million. Earnings per diluted share from continuing operations ex-items was $0.20 for the quarter, up from $0.18 last quarter and was $0.71 for the full year of 2021. GAAP earnings per diluted share from continuing operations was $0.06 for the quarter and $0.43 for the full year. Now moving on to the balance sheet. Receivables were $96.8 million an increased approximately $1.5 million from last quarter. However, our DSOs for the fourth quarter improved and were at 65 days compared to 68 days last quarter. Inventory finished the year at $45.4 million, up approximately $1.3 million from last quarter end. Inventory turns for the quarter remained consistent at 2.4, which is comparable to last quarter. As previously highlighted, the company continues to experience an increase in cost of raw materials, labor, packaging and transportation costs, which are increasing the cost of inventory. Additionally, challenges on the supply chain persist which will continue to require carrying a larger amount of inventory to help mitigate disruptions. On the liability side of the balance sheet, our long-term debt was $190 million at December 31, 2021, significantly reduced from $261 million at the end of 2020. And considering cash of $18 million, net debt was $172 million at year-end or a decrease of $75 million from last year-end. Our leverage ratio was 2.08 as we exited 2021 and down from over 2.8 last year. As Larry mentioned earlier, the company made significant progress during the year as we will continue to maintain our efforts towards reducing the debt leverage of the company. Our debt is currently comprised of our senior notes at $135 million as well as $55 million outstanding under our bank revolving credit facility. Looking at cash flow for the fourth quarter of 2021, cash flow from operating activities was $7.2 million and after paying for $4.8 million of CapEx, our free cash flow was $2.4 million for the quarter. CapEx for the fourth quarter also includes $1 million associated with facility repair costs, which were covered by insurance. Additionally, cash from operations for the quarter was negatively impacted by a build in working capital which includes a $4.3 million prepayment to renew the company's corporate insurance programs for 2022. Looking forward to 2022, we expect CapEx to modestly expand but will continue to be aligned with activity levels and remain in line with historical levels while in a growth period. For the full year of 2022, we expect capital expenditures to be in the range of $15 million to $18 million. Core will continue to -- our strict capital discipline and asset-light business model with capital expenditures primarily targeted at growth opportunities and initiatives. This also marks another quarter and the 20th consecutive year, Core Lab has generated positive free cash flow, and we are projecting to continue generating positive free cash as we look ahead to 2022 and beyond. We believe a company's ability to generate free cash and free cash flow yield is an important metric for shareholders when comparing company's financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I will now turn it over to Gwen for an update on our guidance and outlook.